Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development ...

Remuseum’s second report concludes that admission fees are raising few funds and keeping out potential visitors—and ...

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of ...

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on ...

Critical Metals Corp recently announced its maiden SK1300 report for the Tanbreez Project of 45MT (consisting of 19.5 million ...

The Company reported a record full-year billed revenue of $32.9M (CAD $47M) in 2024, representing a year-over-year increase of 39% from 2023.The Company recorded its highest-ever quarterly billed reve ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

Q4 2024 Earnings Call Transcript March 20, 2025 Abeona Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.24, ...

As Illinois House members consider regulating homeschools and private schools, Illinois Policy and parents across Illinois ...

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, ...